secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001104659-24-107219
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea reports preliminary cash of $26.2M; CMO Mirza steps down, engages Dr. Pultar as advisor
--------------------------------------------------------------------------------

- Preliminary cash and equivalents ~$26.2M as of Sep 30, 2024, down from $28.7M at Jun 30, 2024.
- Dr. Nadeem Mirza steps down as CMO effective Oct 9, 2024; will remain through Dec 13, 2024.
- Engaged Dr. Philippe Pultar as Senior Medical Advisor to lead WEE1 inhibitor APR-1051 Phase 1 trial.
- Patient enrollment ongoing in Phase 1 ACESOT-1051 study for APR-1051; update expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465924107219/0001104659-24-107219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465924107219/tm2425851d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-107219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer